Cargando…
Biology of Mesothelin and Clinical Implications: A Review of Existing Literature
Since its discovery in 1992, mesothelin (MSLN) has generated significant interest as a therapeutic target. A number of characteristics make it ideal for this purpose. First, it is not expressed on the parenchyma of any vital organs. Second, it is differentially expressed on a number of cancer types...
Autores principales: | Hagerty, Brendan L., Takabe, Kazuaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588497/ https://www.ncbi.nlm.nih.gov/pubmed/37869242 http://dx.doi.org/10.14740/wjon1655 |
Ejemplares similares
-
Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
por: Hagerty, Brendan L., et al.
Publicado: (2020) -
Mesothelin as a biomarker for targeted therapy
por: Lv, Jiang, et al.
Publicado: (2019) -
Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017) -
Challenges of Anti-Mesothelin CAR-T-Cell Therapy
por: Zhai, Xuejia, et al.
Publicado: (2023) -
The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment
por: Hilliard, Tyvette S.
Publicado: (2018)